Website
www.epitopea.com
Email
Alan.Rigby@epitopea.com
LinkedIn
Visit our page
Line of business
Immunotherapeutics
Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped tumor-specific antigens, which are known as CryptigenTM TSAs, that are broadly shared across multiple patients with the same tumor type.